Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary DiseaseA Randomized, Placebo-Controlled, Double-Blind, Crossover Study

被引：0
作者：
Mario Cazzola
Pierluigi Paggiaro
Paolo Palange
Leif Bjermer
Pilar Ausin
Lars-Goran Carlsson
Jan Ekelund
Jan Lotvall
机构：
[1] Postgraduate School of Respiratory Medicine University of Rome ‘Tor Vergata’,Unit of Respiratory Clinical Pharmacology Department of Internal Medicine
[2] San Raffaele Pisana Hospital,Department of Pulmonary Rehabilitation
[3] IRCCS,Cardiothoracic and Vascular Department
[4] University of Pisa,Department of Clinical Medicine
[5] University of Rome La Sapienza,Department of Respiratory Medicine & Allergology
[6] University Hospital,Department of Internal Medicine, Krefting Research Centre, Sahlgrenska Academy
[7] Hospital del Mar-IMIM-CIBERES,undefined
[8] AstraZeneca R&D,undefined
[9] University of Gothenburg,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷
关键词：
Chronic Obstructive Pulmonary Disease; Chronic Obstructive Pulmonary Disease Patient; Salmeterol; Formoterol; Moderate Chronic Obstructive Pulmonary Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Bronchodilator therapy is central to the symptomatic management of chronic obstructive pulmonary disease (COPD), and treatment with short-acting bronchodilators is recommended in patients with mild COPD.
引用
收藏
页码：147 / 155
页数：8
相关论文
共 70 条
[1]  
Partridge M.R.(2009)Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey Curr Med Res Opin 25 2043-8
[2]  
Karlsson N.(2009)Effect on lung function and morning activities of budesonide/ formoterol versus salmeterol/fluticasone in patients with COPD Ther Adv Respir Dis 3 1-11
[3]  
Small I.R.(2010)Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD Eur Respir J 36 96-104
[4]  
Partridge M.R.(1994)Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease Pulm Pharmacol 7 103-7
[5]  
Schuermann W.(2004)Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD Pulm Pharmacol Ther 17 121-5
[6]  
Beckman O.(1999)Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action Respiration 66 434-9
[7]  
Partridge M.R.(2009)Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study Pulm Pharmacol Ther 22 44-9
[8]  
Miravitlles M.(2002)Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study Can Respir J 9 107-15
[9]  
Ståhl E.(2007)Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction Respirology 12 732-9
[10]  
Cazzola M.(2006)Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD Respiration 73 414-9
1234567